Clinical Trial Update: A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes. [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Insulin 287 Once a Week to insulin glargine once daily in people with Type 2 diabetes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin 287 (NNC0148-0287 C)
• Insulin glargine (100 Units/mL) (insulin glargine)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2021-02-01